CUAMC
China Universal Asset Management Company’s Keros Therapeutics KROS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $109K | Buy |
8,157
+21
| +0.3% | +$280 | 0.01% | 361 |
|
|
2025
Q1 | $82.9K | Sell |
8,136
-453
| -5% | -$4.62K | 0.01% | 372 |
|
|
2024
Q4 | $136K | Buy |
8,589
+1,372
| +19% | +$21.7K | 0.01% | 363 |
|
|
2024
Q3 | $419K | Buy |
7,217
+2,978
| +70% | +$173K | 0.05% | 238 |
|
|
2024
Q2 | $194K | Sell |
4,239
-2,677
| -39% | -$122K | 0.03% | 248 |
|
|
2024
Q1 | $458K | Buy |
6,916
+3,456
| +100% | +$229K | 0.06% | 190 |
|
|
2023
Q4 | $138K | Buy |
3,460
+2,702
| +356% | +$107K | 0.03% | 247 |
|
|
2023
Q3 | $24.2K | Buy |
758
+370
| +95% | +$11.8K | 0.01% | 288 |
|
|
2023
Q2 | $15.6K | Buy |
388
+15
| +4% | +$603 | ﹤0.01% | 288 |
|
|
2023
Q1 | $15.9K | Buy |
373
+93
| +33% | +$3.97K | 0.01% | 244 |
|
|
2022
Q4 | $13.4K | Buy |
280
+39
| +16% | +$1.87K | 0.01% | 207 |
|
|
2022
Q3 | $9K | Buy |
+241
| New | +$9K | ﹤0.01% | 216 |
|